Pharmagen, Inc.
PHRX
$0.00
$0.000.00%
OTC PK
| 03/31/2014 | 12/31/2013 | 09/30/2013 | 06/30/2013 | 03/31/2013 | |
|---|---|---|---|---|---|
| Revenue | -23.34% | 2.83% | -39.70% | -1.26% | 259.95% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -23.34% | 2.83% | -39.70% | -1.26% | 259.95% |
| Cost of Revenue | -15.08% | -51.13% | -73.85% | -27.02% | 158.86% |
| Gross Profit | -28.83% | 232.31% | 170.39% | 14.71% | 385.82% |
| SG&A Expenses | -15.80% | 38.24% | 68.47% | -3.51% | 214.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.56% | -1.51% | -24.11% | -9.61% | 193.57% |
| Operating Income | -25.34% | 6.80% | -24.25% | 27.16% | -49.07% |
| Income Before Tax | 15.35% | -152.14% | -29.87% | -216.58% | -145.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 15.35% | -152.14% | -29.87% | -216.58% | -145.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.35% | -152.14% | -29.87% | -216.58% | -145.21% |
| EBIT | -25.34% | 6.80% | -24.25% | 27.16% | -49.07% |
| EBITDA | -23.15% | 9.98% | -21.63% | 30.78% | -47.66% |
| EPS Basic | 22.73% | -180.00% | -32.14% | -200.00% | -83.33% |
| Normalized Basic EPS | 35.71% | -6.25% | -5.56% | -200.00% | -75.00% |
| EPS Diluted | 22.73% | -180.00% | -32.14% | -200.00% | -83.33% |
| Normalized Diluted EPS | 35.71% | -6.25% | -5.56% | -200.00% | -75.00% |
| Average Basic Shares Outstanding | 25.99% | 9.30% | -0.56% | 4.67% | 34.97% |
| Average Diluted Shares Outstanding | 25.99% | 9.30% | -0.56% | 4.67% | 34.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |